Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.03 +1.91%

+$0.03 today

Market cap
$115.05M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.50M

Average 0.07M

Income Statement

Follow revenue through to earnings.

Revenue

$2.79M

FY 2025 · Annual

-77.9% YoY

Operating Income

-$53.42M

FY 2025 · Annual

Net Income

-$49.18M

FY 2025 · Annual

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.11M57.67M51.9M12.62M2.79M
Cost of Revenue47M51.66M56.02M51.98M0
Gross Profit(22.3M)6.01M5.62M12.62M2.79M
Gross Margin-184.1%10.4%10.8%100.0%100.0%
Research & Development47M51.66M56.02M51.98M43.62M
Selling, General & Admin25.52M14.47M11.75M11.93M11M
Operating Expenses25.52M63.44M18.29M64.2M56.21M
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
EBITDA(43.23M)(12.28M)(1.84M)(46.91M)(43.65M)
EBITDA Margin-356.9%-21.3%-3.5%-371.7%-1566.1%
Operating Income(47.83M)(57.43M)(12.67M)(51.58M)(53.43M)
Operating Margin-394.9%-99.6%-24.4%-408.6%-1916.9%
Interest Income327K546K3.18M2.44M1.32M
Interest Expense312K288K640K566K440K
Other Income / Expenses2.35M(547K)5.1M2.1M4.25M
Income Before Tax(45.48M)(57.97M)(7.57M)(49.47M)(49.18M)
Pre-Tax Margin-375.5%-100.5%-14.6%-392.0%-1764.5%
Income Tax Expense00000
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Net Margin-436.0%-100.7%-14.6%-392.0%-1764.5%
EPS (Basic)(0.57)(0.73)(0.09)(0.61)(0.53)
EPS (Diluted)(0.57)(0.73)(0.09)(0.61)(0.53)
Weighted Avg Shares79.54M79.59M84.11M81.05M89.42M
Weighted Avg Shares (Diluted)79.54M79.64M84.11M81.05M89.42M

IPHA Earnings Waterfall · TTM

NASDAQ:IPHA · Revenue to Net Income

Key Ratios

EPS$-1.16
Gross Margin2321.8%
Net Margin-2064.7%
P/E Ratio-1.4
P/S Ratio124.0

Analysis

$15.4M of revenue converted into -$98.4M of net income for the selected period. Gross margin is 2321.8% and net margin is -2064.7%, showing how much revenue survives after costs and taxes. EPS is $-1.16, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 12, 2026
6-K6-K filingNov 5, 2026
6-K6-K filingOct 27, 2026
6-K6-K filingOct 21, 2026
6-K6-K filingOct 20, 2026

How much revenue does IPHA generate?

Innate Pharma S.A. (IPHA) reported $2.79M of revenue in fiscal 2025.

Is IPHA profitable?

Innate Pharma S.A. (IPHA) reported -$49.18M of net income, with a net margin of -1764.5%.